High‑performance custom miRNA mimic (agomir) and anti-miR synthesis with LNA, 2′ modifications, PS backbones, conjugation, labeling, purification, and LC-MS QC from discovery to preclinical.
MicroRNAs (miRNAs) are ~22-nt regulatory RNAs that direct the RNA-induced silencing complex (RISC) to partially complementary target sequences, resulting in translational repression and mRNA destabilization1,2. Synthetic miRNA tools enable precise modulation of gene networks: miRNA mimics (agomirs) restore or amplify endogenous miRNA function (gain-of-function), while antagomirs (anti‑miRs) selectively inhibit native miRNAs to induce controlled loss-of-function effects.
Because these modalities operate through distinct mechanistic pathways, their engineering strategies differ fundamentally. Mimics are optimized to promote efficient guide strand Ago loading while minimizing passenger strand activity to ensure accurate RISC engagement. In contrast, anti‑miRs are engineered for high binding affinity, nuclease resistance, and functional durability to effectively compete with abundant, protein-associated miRNAs in complex biological systems.
At Bio-Synthesis, we serve as a technical partner for high-performance custom miRNA mimic (agomir) duplex synthesis and antagomir / anti‑miR inhibitor manufacturing. Our platform supports advanced chemistries including LNA, 2′-O-Me, 2′-F, 2′-MOE, and phosphorothioate (PS) backbone configurations, along with delivery-focused conjugations (cholesterol, GalNAc, PEG) and labeling options (FAM/Cy dyes, biotin). Integrated purification strategies and analytical validation (HPLC, LC-MS, COA) enable seamless progression from discovery through preclinical development.
Guide loading + passenger suppression
High affinity • nuclease resistance
Stability, affinity, immune profile
HPLC + LC‑MS + COA
RNase‑free lyophilized oligos (or solution), optional duplex annealing, and documentation (COA + chromatography + MS) aligned to program stage.
For duplex RNA modalities, see siRNA manufacturing. For antisense programs, explore ASO manufacturing. For delivery strategies, see receptor‑targeted oligonucleotide conjugation and oligo‑lipid conjugation.
Restore a downregulated miRNA and observe target repression and phenotype rescue.
Block an oncomiR or pathway‑driving miRNA to de‑repress targets and test causality.
Dose‑response and kinetics profiling across chemistries for robust, interpretable hits.
Stabilized anti‑miRs with conjugation/formulation for tissue‑directed inhibition.
Mimics (agomirs) aim to reproduce native miRNA loading and targeting, while inhibitors (antagomirs/anti‑miRs) bind the mature miRNA and block function. Chemistry and positional choices tune the balance between potency, specificity, durability, and developability.
Transfection, nanoparticles, or conjugation‑enabled uptake (design‑dependent).
Mimic: Ago loading of guide strand. anti‑miR: antisense binding to mature miRNA.
Mimic: target repression. anti‑miR: de‑repression (loss of miRNA activity).
Use this table as a practical decision guide when selecting format, chemistry depth, and controls.
We manufacture custom miRNA mimic oligonucleotides with flexible chemistry patterns and scalable production workflows.
Agomir duplex design support (strand bias, passenger suppression), optional duplex annealing and verification.
High‑affinity inhibitor builds including LNA anti‑miR synthesis, 2′ chemistries, and end protection.
PO/PS mixing strategies to balance stability, affinity, exposure, and specificity (program‑dependent).
Cholesterol‑conjugated antagomirs and GalNAc‑anti‑miRs for tissue‑strategy workflows; PEG and lipid variants on request.
FAM/Cy3/Cy5 and biotin options for uptake tracking, imaging, and pull‑down assays.
HPLC/PAGE options, LC‑MS confirmation (as applicable), OD260, and documentation packages (COA + traces).
Send the miRNA ID/species, format (mimic vs anti‑miR), in vitro vs in vivo intent, preferred chemistry (LNA/2′/PS), conjugation/label needs, purification level, QC package, and target scale.
Chemical optimization is central to stability, affinity, specificity, immune profile, and delivery compatibility. Mimics often use selective patterns to preserve Ago loading; anti‑miRs often use heavier stabilization for potency and durability.
Many in vivo inhibitor workflows emphasize PS backbone + 2′ chemistries and/or LNA blocks, then tune distribution with conjugation or formulation. The optimal pattern is tissue/route‑dependent.
We execute miRNA programs with CDMO-level chemistry control, scalable manufacturing workflows, and documentation aligned to progression from discovery through preclinical development.
Synthesis and purification workflows that can transition from mg to larger preclinical quantities (program‑dependent).
COA, analytical traces, and batch summaries; additional documentation can be aligned to your development stage.
Orthogonal analytics and optional tests (endotoxin/bioburden, stability) selected based on route, model, and regulatory pathway intent.
miRNA tools introduce chemistry‑ and format‑driven CQAs such as duplex integrity (mimics), modification completeness, and close‑running impurity profiles. Our workflow supports program progression with scalable execution and documentation.
Desalt / cartridge / HPLC / PAGE options aligned to length, chemistry, and downstream use.
HPLC purity profiling + LC‑MS identity confirmation (as applicable), plus OD260 quantitation.
Optional duplex annealing and confirmation support for miRNA mimics (design‑dependent).
COA (as applicable), chromatography traces, MS spectra/confirmation (as applicable), and batch summary aligned to project stage. Optional testing can be added based on requirements (e.g., endotoxin/bioburden, stability assessments).
miRNA mimics and inhibitors are used across functional biology, target validation, pathway modulation, and preclinical proof‑of‑concept—especially when paired with controls and orthogonal readouts.
Gain/loss perturbations, reporter assays, pathway readouts, and target confirmation.
Chemistry panels and dose‑response sets to prioritize robust, interpretable phenotypes.
Stabilized anti‑miRs with conjugation/formulation to tune exposure and durability.
Scrambled negative controls, seed‑mutant controls, passenger controls (mimics), multiple independent designs, and dose‑ranging help separate on‑target miRNA biology from chemistry‑ or delivery‑driven artifacts.
The highest‑impact technical levers are: (i) Ago loading and strand selection (mimics), (ii) seed‑driven specificity and off‑target control, and (iii) affinity + exposure constraints for anti‑miRs. Use this section as a checklist for building robust, scale‑aligned designs.
Engineer duplex asymmetry to favor guide loading, and suppress passenger activity with mismatches and/or heavier passenger modifications. Over‑stabilizing the guide can reduce productive Ago loading—optimize the minimum chemistry needed for stability and performance.
Seed pairing drives much of the regulatory network. Use seed‑mutant controls and multiple independent designs, and consider transcriptome‑level validation (RNA‑seq + motif enrichment) when phenotypes are complex or surprising.
anti‑miRs must compete with abundant, protein‑associated miRNAs. LNA blocks and 2′ chemistry patterns increase affinity; PS content increases stability and exposure, but excessive PS can increase non‑specific binding. Optimize affinity first, then tune distribution/durability via backbone/conjugation/formulation.
Sampling windows can shift with chemistry and delivery. Profile early vs late timepoints, and use dose‑response series rather than single‑dose conclusions. Plan for durability when interpreting in vivo inhibitor effects.
Uptake confirmation • dose‑response • on‑target engagement (reporter + endogenous targets) • independent designs • robust controls.
They are often used interchangeably. “Antagomir” frequently implies a heavily stabilized inhibitor (e.g., PS + 2′ chemistry ± LNA and sometimes a conjugation) intended for durable inhibition.
Yes. We provide custom miRNA mimic duplex synthesis with options for strand bias engineering, passenger suppression, optional duplex annealing, and purification/QC aligned to your study stage.
Yes. We support LNA‑modified anti‑miR inhibitor synthesis (positional block patterns on request) and can combine LNA with 2′ chemistries and PS backbone strategies for potency and durability.
Yes. We manufacture PS antagomirs and mixed PO/PS designs to tune stability/exposure while managing specificity (program‑dependent optimization).
Yes. We support cholesterol‑conjugated antagomirs and GalNAc‑anti‑miR synthesis (design‑ and route‑dependent). We can also discuss PEG or lipid variants depending on delivery strategy.
Common options include 2′‑O‑Me, 2′‑F, and 2′‑O‑MOE. Mimics often use selective patterns to preserve Ago loading; inhibitors often use heavier stabilization for affinity and durability.
miRNA ID/species, format (mimic vs inhibitor), intended use (in vitro/in vivo), desired chemistries (LNA/2′/PS), conjugations/labels, purification, QC package, and target scale.
For reproducibility, HPLC is commonly chosen. PAGE can be used for demanding separations. Early screening may use simpler purification depending on goals and budget.
Typical QC includes HPLC purity profiling, LC‑MS identity confirmation (as applicable), and OD260 quantitation with COA. Optional testing (e.g., endotoxin/bioburden, duplex verification, stability) can be added by stage.
Use dose‑response, seed‑mutant controls, and independent designs. For mimics, suppress passenger loading via sequence/chemistry. Consider transcriptome‑level validation when phenotypes are complex.
Share your target miRNA and intended use (mimic vs inhibitor), chemistry preferences (2′/LNA/PS), any conjugation/label needs, purification level, QC/documentation requirements, and scale target. We’ll align design, synthesis, purification, and analytics to your stage.
Selected publications relevant to folate receptor targeting, ligand conjugation, and oligonucleotide delivery chemistry.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.